Cadila Healthcare - Zydus Lifesciences Share Price

  • 987.653.05 (0.31%)
  • Volume: 7,45,052
  • Closed
  • Last Updated On: 17 Oct, 2025, 03:51 PM IST
High: "1311.00",Open: "1036.04",Low: "850.00",
Loading...
Cadila Healthcare - Zydus Lifesciences Share Price
  • 987.653.05 (0.31%)
  • Volume: 7,45,052
Advertisment
Stock Recommendations
  • Potential
    Upside

  • 1 Year
    Target

HOLD

Mean Recos by
26 Analysts

2

3

12

5

4

Strong Sell

Sell

Hold

Buy

Strong Buy

Unlock Potential Upside
Stock Reports Plus

/10

Stock Score

View Report
Earnings
Fundamentals
Relative Valuation
Risk
Price Momentum
No Rating (NR)
Negative
Neutral
Positive
Unlock Stock Score

Key Metrics

PE Ratio
(x)
21.68
EPS - TTM
(₹)
45.56
MCap
(₹ Cr.)
99,380.70
Sectoral MCap Rank
7
PB Ratio
(x)
3.76
Div Yield
(%)
1.11
Face Value
(₹)
1.00
Beta

Beta

1 Month1.50
3 Months1.42
6 Months1.14
1 Year0.99
3 Years1.11

1.50
VWAP
(₹)
984.79
52W H/L
(₹)
1,059.05 / 795.00

Cadila Healthcare share price insights

View All
  • Company's annual revenue growth of 18.55% outperformed its 3 year CAGR of 14.76%. (Source: Consolidated Financials)

  • 5 day moving crossover appeared on Oct 17, 2025. Average price gain of 2.52% within 7 days of this signal in last 5 years.

  • Company has spent less than 1% of its operating revenues towards interest expenses and 15.84% towards employee cost in the year ending Mar 31, 2025. (Source: Consolidated Financials)

  • Zydus Lifesciences Ltd. share price moved up by 0.31% from its previous close of Rs 984.60. Zydus Lifesciences Ltd. stock last traded price is 987.65

    Share PriceValue
    Today/Current/Last987.65
    Previous Day984.60984.00

InsightsCadila Healthcare

    Do you find these insights useful?

    • hate it

    • meh

    • love it

    Cadila Healthcare Share Price Returns

    1 Day0.31%
    1 Week-0.58%
    1 Month-4.46%
    3 Months0.5%
    1 Year-3.25%
    3 Years135.8%
    5 Years129.47%

    ET Stock ScreenersTop Score Companies

    Check whether Cadila Healthcare belongs to analysts' top-rated companies list?

    View Stock Screeners

    Cadila Healthcare Share Recommendations

    Recent Recos

    HOLD

    Current

    Mean Recos by 26 Analysts

    Strong
    Sell
    SellHoldBuyStrong
    Buy
    • Target₹1090
    • OrganizationJM Financial
    • HOLD
    • Target₹1078
    • OrganizationSharekhan by BNP Paribas
    • BUY

    Analyst Trends

    RatingsCurrent1 Week Ago1 Month Ago3 Months Ago
    Strong Buy4433
    Buy5556
    Hold12121312
    Sell3333
    Strong Sell2222
    # Analysts26262626

    Cadila Healthcare Financials

    • Insights

      • Beating 3 Yr Revenue CAGR

        Company's annual revenue growth of 18.55% outperformed its 3 year CAGR of 14.76%. (Source: Consolidated Financials)
      • Employee & Interest Expense

        Company has spent less than 1% of its operating revenues towards interest expenses and 15.84% towards employee cost in the year ending Mar 31, 2025. (Source: Consolidated Financials)
      Quarterly | AnnualJun 2025Mar 2025Dec 2024Sep 2024Jun 2024
      Total Income6,728.606,608.505,326.605,305.206,270.70
      Total Income Growth (%)1.8224.070.40-15.4010.20
      Total Expenses4,723.304,859.904,110.504,009.204,338.80
      Total Expenses Growth (%)-2.8118.232.53-7.605.60
      EBIT2,005.301,748.601,216.101,296.001,931.90
      EBIT Growth (%)14.6843.79-6.17-32.9222.15
      Profit after Tax (PAT)1,466.801,170.901,026.20920.201,482.50
      PAT Growth (%)25.2714.1011.52-37.9318.97
      EBIT Margin (%)29.8026.4622.8324.4330.81
      Net Profit Margin (%)21.8017.7219.2717.3523.64
      Basic EPS (₹)14.5811.6410.179.0614.11
      Quarterly | AnnualJun 2025Mar 2025Dec 2024Sep 2024Jun 2024
      Total Income2,745.406,005.002,593.402,947.304,266.80
      Total Income Growth (%)-54.28131.55-12.01-30.9215.52
      Total Expenses2,132.902,174.901,999.001,812.101,917.90
      Total Expenses Growth (%)-1.938.8010.31-5.520.81
      EBIT612.503,830.10594.401,135.202,348.90
      EBIT Growth (%)-84.01544.36-47.64-51.6731.14
      Profit after Tax (PAT)384.702,813.70470.60789.801,700.80
      PAT Growth (%)-86.33497.90-40.42-53.5621.04
      EBIT Margin (%)22.3163.7822.9238.5255.05
      Net Profit Margin (%)14.0146.8618.1526.8039.86
      Basic EPS (₹)3.8227.964.687.8516.90
      Quarterly | Annual FY 2025 FY 2024 FY 2023 FY 2022 FY 2021
      Total Revenue23,511.0019,831.5017,424.0015,489.9014,449.10
      Total Revenue Growth (%)18.5513.8212.497.200.57
      Total Expenses17,264.7015,008.4014,230.1012,764.5011,844.80
      Total Expenses Growth (%)15.035.4711.487.76-5.30
      Profit after Tax (PAT)4,525.503,859.501,960.304,487.302,133.60
      PAT Growth (%)17.2696.88-56.31110.3281.34
      Operating Profit Margin (%)27.5825.0819.2818.6819.18
      Net Profit Margin (%)19.4719.7411.3729.3914.81
      Basic EPS (₹)44.9738.1419.3043.8320.84
      Quarterly | Annual FY 2025 FY 2024 FY 2023 FY 2022 FY 2021
      Total Revenue15,812.5011,903.509,280.008,160.607,869.30
      Total Revenue Growth (%)32.8428.2713.723.709.34
      Total Expenses8,367.807,655.107,044.006,677.405,993.30
      Total Expenses Growth (%)9.318.685.4911.417.27
      Profit after Tax (PAT)5,774.903,441.501,529.20857.901,476.20
      PAT Growth (%)67.80125.0578.25-41.884.48
      Operating Profit Margin (%)52.3142.8828.7920.2725.02
      Net Profit Margin (%)38.2031.8117.5110.7418.97
      Basic EPS (₹)57.3934.0115.068.3814.42

      All figures in Rs Cr, unless mentioned otherwise

    • Annual FY 2025 FY 2024 FY 2023 FY 2022 FY 2021
      Total Assets37,201.7029,280.8025,756.4027,795.4023,884.70
      Total Assets Growth (%)27.0513.68-7.3416.370.84
      Total Liabilities10,843.307,179.206,068.108,741.608,955.10
      Total Liabilities Growth (%)51.0418.31-30.58-2.38-25.23
      Total Equity26,358.4022,101.6019,688.3019,053.8014,929.60
      Total Equity Growth (%)19.2612.263.3327.6227.49
      Current Ratio (x)1.892.151.811.561.11
      Total Debt to Equity (x)0.130.040.070.250.35
      Contingent Liabilities1,428.001,277.101,315.201,210.701,295.50
      Annual FY 2025 FY 2024 FY 2023 FY 2022 FY 2021
      Total Assets32,316.9024,084.8020,563.6017,740.0018,463.60
      Total Assets Growth (%)34.1817.1215.92-3.9211.55
      Total Liabilities11,126.808,368.306,924.204,499.505,719.10
      Total Liabilities Growth (%)32.9620.8653.89-21.338.08
      Total Equity21,190.1015,716.5013,639.4013,240.5012,744.50
      Total Equity Growth (%)34.8315.233.013.8913.18
      Current Ratio (x)1.953.122.571.701.25
      Total Debt to Equity (x)0.390.390.350.200.31
      Contingent Liabilities1,737.701,750.30752.402,233.102,009.30

      All figures in Rs Cr, unless mentioned otherwise

    • Insights

      • Increase in Cash from Investing

        Company has used Rs 8372.3 cr for investing activities which is an YoY increase of 467.54%. (Source: Consolidated Financials)
      Annual FY 2025 FY 2024 FY 2023 FY 2022 FY 2021
      Net Cash flow from Operating Activities6,776.703,227.902,688.802,104.103,293.90
      Net Cash used in Investing Activities-8,372.30-1,475.201,171.201,154.40-724.60
      Net Cash flow from Financing Activities2,014.20-1,810.40-4,400.40-868.30-2,547.70
      Net Cash Flow413.80-74.80-533.802,372.90-90.50
      Closing Cash & Cash Equivalent826.80413.00573.103,460.101,087.20
      Closing Cash & Cash Equivalent Growth (%)100.19-27.94-83.44218.26-7.68
      Total Debt/ CFO (x)0.470.240.431.991.39
      Annual FY 2025 FY 2024 FY 2023 FY 2022 FY 2021
      Net Cash flow from Operating Activities3,114.001,999.101,078.201,310.702,225.30
      Net Cash used in Investing Activities-4,503.60-1,830.60-1,959.70768.20-2,713.80
      Net Cash flow from Financing Activities1,384.50-300.80827.00-1,709.80257.20
      Net Cash Flow-5.10-132.30-54.50369.10-231.30
      Closing Cash & Cash Equivalent103.00108.10248.10523.10154.00
      Closing Cash & Cash Equivalent Growth (%)-4.72-56.43-52.57239.68-60.03
      Total Debt/ CFO (x)2.683.094.472.031.76

      All figures in Rs Cr, unless mentioned otherwise

    • Annual FY 2025 FY 2024 FY 2023 FY 2022 FY 2021
      Return on Equity (%)18.8919.4611.1926.3916.42
      Return on Capital Employed (%)22.7720.4816.4314.2917.24
      Return on Assets (%)12.1613.187.6116.148.93
      Interest Coverage Ratio (x)44.1769.8131.1528.0721.62
      Asset Turnover Ratio (x)0.700.710.640.380.37
      Price to Earnings (x)19.7226.2525.387.9621.19
      Price to Book (x)3.725.102.842.103.47
      EV/EBITDA (x)12.5218.1812.9711.4614.79
      EBITDA Margin (%)31.5228.9923.4723.3523.83
      Annual FY 2025 FY 2024 FY 2023 FY 2022 FY 2021
      Return on Equity (%)27.2521.8911.216.4711.58
      Return on Capital Employed (%)32.3221.5314.1411.8014.27
      Return on Assets (%)17.8614.287.434.837.99
      Interest Coverage Ratio (x)18.1813.1610.7915.5433.82
      Asset Turnover Ratio (x)0.540.480.460.440.44
      Price to Earnings (x)15.4329.4132.5741.6730.58
      Price to Book (x)4.206.433.652.703.54
      EV/EBITDA (x)11.5420.7818.0918.1520.39
      EBITDA Margin (%)55.7847.5434.3926.2630.82

    Financial InsightsCadila Healthcare

    • Income (P&L)
    • Cash Flow
      • Beating 3 Yr Revenue CAGR

        Company's annual revenue growth of 18.55% outperformed its 3 year CAGR of 14.76%. (Source: Consolidated Financials)

      • Employee & Interest Expense

        Company has spent less than 1% of its operating revenues towards interest expenses and 15.84% towards employee cost in the year ending Mar 31, 2025. (Source: Consolidated Financials)

      • Increase in Cash from Investing

        Company has used Rs 8372.3 cr for investing activities which is an YoY increase of 467.54%. (Source: Consolidated Financials)

    Do you find these insights useful?

    • hate it

    • meh

    • love it

    Cadila Healthcare Share Price Forecast

    • Get multiple analysts’ prediction on Cadila Healthcare

      Stock Forecast Non Prime User
      • High, low, medium predictions for Price
      • Upcoming predictions for Revenue
      • Details about company earnings
      START FREE TRIAL
    • Get multiple analysts’ prediction on Cadila Healthcare

      Stock Forecast Non Prime User
      • High, low, medium predictions for Price
      • Upcoming predictions for Revenue
      • Details about company earnings
      START FREE TRIAL
    • Get multiple analysts’ prediction on Cadila Healthcare

      Stock Forecast Non Prime User
      • High, low, medium predictions for Price
      • Upcoming predictions for Revenue
      • Details about company earnings
      START FREE TRIAL

    Cadila Healthcare Technicals

    • Bullish / Bearish signals for Cadila Healthcare basis selected technical indicators and moving average crossovers.

      5 Day EMA Crossover

      Bullish signal on daily chart

      Appeared on: 17 Oct 2025

      5D EMA: 985.71

      Last 4 Buy Signals:9 Oct 2025
      Date7 days Gain/Loss %
      9 Oct 20251.56%
      6 Oct 20250.74%
      23 Sep 20250.34%
      18 Sep 20251.07%

      Average price gain of 2.52% within 7 days of Bullish signal in last 5 years

      Heikin-Ashi Changeover

      Bullish indication on daily chart

      • Prev. Close Price

        985.18

      • LTP

        987.65

      Formed on:17 Oct 2025

      On daily price chart, Heikin-Ashi candle changed from Red to Green

    • 44%
      Positive Movement since
      1st Jan 2005 on basis
      55%
      Negative Movement since
      1st Jan 2005 on basis
      Exclude
    • Pivot Levels

      R1R2R3PIVOTS1S2S3
      Classic993.08998.521011.47985.57980.13972.62959.67

      Average True Range

      5 DAYS14 DAYS28 DAYS
      ATR17.3019.3219.89

    Cadila Healthcare Peer Comparison

      • 1D
      • 1W
      • 1M
      • 3M
      • 6M
      • 1Y
      • 5Y
      Loading...
    • Ratio Performance

      NAMEP/E (x)P/B (x)ROE %ROCE %ROA %Rev CAGR [3Yr]OPMNPMBasic EPSCurrent RatioTotal Debt/ Equity (x)Total Debt/ CFO (x)
      Cadila Healthcare21.683.7718.8922.7712.1614.7627.5819.8544.971.890.130.47
      Cipla23.634.0716.9021.5714.108.7324.9819.2065.294.250.000.02
      Torrent Pharma60.5915.9825.1728.7112.759.7525.6116.5956.471.190.401.17
      Dr. Reddys18.453.0916.8521.8111.4415.1124.3217.4767.891.920.120.90
      Mankind Pharma54.017.0213.8913.277.1716.7224.0316.3749.281.230.593.51
      Add More
      Annual Ratios (%)

      Choose from Peers

      • Lupin
      • Alkem Labs
      • Aurobindo Pharma
      • Glenmark Pharma
      • Laurus Labs

      Choose from Stocks

      Peers InsightsCadila Healthcare

        Do you find these insights useful?

        • hate it

        • meh

        • love it

        Cadila Healthcare Shareholding Pattern

        • Loading...
          Showing Cadila Healthcare Shareholding as on Sep 2025
          CategorySep 2025Jun 2025Mar 2025Dec 2024
          Promoters74.9974.9974.9974.98
          Pledge0.000.000.000.00
          FII7.347.137.317.53
          DII10.8411.0910.9310.61
          Mutual Funds4.705.566.366.32
          Others6.826.796.776.87
        • Showing Shareholding as on Sep 2025
          CategoryNo. of SharesPercentage% Change QoQ
          Promoters75,46,24,31474.99 %0.00
          Pledge00.00 %0.00
          FII7,38,68,8007.34 %0.20
          DII10,90,38,11310.84 %-0.25
          MF4,72,96,8594.70 %-0.85
          Others6,87,02,7636.82 %0.03

        Cadila Healthcare MF Ownership

        MF Ownership as on 30 September 2025

        Cadila Healthcare F&O Quote

          • Expiry

          Price

          988.903.15 (0.32%)

          Open Interest

          72,71,100-332,100 (-4.37%)

          OpenHighLowPrev CloseContracts TradedTurnover (₹ Lakhs)
          982.45993.05977.45985.751,82416,208.07

          Open Interest as of 17 Oct 2025

          • Type
          • Expiry
          • Strike Price

          Price

          13.900.10 (0.72%)

          Open Interest

          2,57,40095,400 (58.89%)

          OpenHighLowPrev CloseContracts TradedTurnover (₹ Lakhs)
          11.8515.6011.0013.807106,377.57

          Open Interest as of 17 Oct 2025

        Cadila Healthcare Corporate Actions

        • Meeting DateAnnounced onPurposeDetails
          Aug 12, 2025Aug 01, 2025Board MeetingQuarterly Results
          Aug 12, 2025May 20, 2025AGM-
          May 20, 2025May 09, 2025Board MeetingAudited Results & Final Dividend
          Feb 05, 2025Jan 21, 2025Board MeetingQuarterly Results
          Nov 12, 2024Oct 30, 2024Board MeetingQuarterly Results
        • TypeDividendDividend per ShareEx-Dividend DateAnnounced on
          Final1100%11.0Jul 25, 2025May 20, 2025
          Final300%3.0Jul 26, 2024May 17, 2024
          Final600%6.0Jul 28, 2023May 18, 2023
          Final250%2.5Jul 28, 2022May 20, 2022
          Final350%3.5Jul 28, 2021May 27, 2021
        • All TypesEx-DateRecord DateAnnounced onDetails
          SplitsOct 06, 2015Oct 07, 2015Aug 12, 2015Split: Old FV5.0| New FV:1.0
          BonusApr 05, 2010Apr 06, 2010Feb 25, 2010Bonus Ratio: 1 share(s) for every 2 shares held
          BonusAug 30, 2006Aug 31, 2006Apr 28, 2006Bonus Ratio: 1 share(s) for every 1 shares held

        About Cadila Healthcare

        Zydus Lifesciences Ltd., incorporated in the year 1995, is a Large Cap company (having a market cap of Rs 99,380.70 Crore) operating in Pharmaceuticals sector. Zydus Lifesciences Ltd. key Products/Revenue Segments include Pharmaceutical Products, Other Operating Revenue and Export Incentives for the year ending 31-Mar-2025. Show More

        • Executives

        • Auditors

        • PR

          Pankaj R Patel

          Chairman
          SP

          Sharvil P Patel

          Managing Director
          GN

          Ganesh N Nayak

          Executive Director
          MM

          Mukesh M Patel

          Non Executive Director
          Show More
        • Deloitte Haskins & Sells LLP

        FAQs about Cadila Healthcare share

        • 1. What's the Cadila Healthcare share price today?
          Cadila Healthcare share price is Rs 987.65 as on 17 Oct, 2025, 03:56 PM IST. Cadila Healthcare share price is up by 0.31% based on previous share price of Rs. 977.3.
        • 2. What is Cadila Healthcare's 52 week high / low?
          52 Week high of Cadila Healthcare share is Rs 1,059.05 while 52 week low is Rs 795.00
        • 3. What is the market cap of Cadila Healthcare?
          Within the Pharmaceuticals sector, Cadila Healthcare stock has a market cap rank of 7. Cadila Healthcare has a market cap of Rs 99,380.70 Cr.
        • 4. What are the returns for Cadila Healthcare share?
          Return Performance of Cadila Healthcare Shares:
          • 1 Week: Cadila Healthcare share price moved down by 0.58%
          • 6 Month: Cadila Healthcare share price moved up by 18.77%
        • 5. What is the PE & PB ratio of Cadila Healthcare?
          The PE ratio of Cadila Healthcare stands at 21.61, while the PB ratio is 3.76.

        Trending in Markets

        Top Gainers As on 03:59 PM | 17 Oct 2025

        Netweb Technologies3,833.10
        2026.30 (112.15%)
        HBL Power936.05
        334.85 (55.70%)
        Anand Rathi Wealth3,125.10
        1082.20 (52.97%)
        Syrma SGS Technology787.00
        258.00 (48.77%)
        Usha Martin455.30
        145.50 (46.97%)

        Top Losers As on 03:59 PM | 17 Oct 2025

        Tata Investment889.00
        -5995.00 (-87.09%)
        Adani Power165.98
        -401.17 (-70.73%)
        Patanjali Foods587.85
        -1092.15 (-65.01%)
        Godfrey Philips3,411.70
        -4767.30 (-58.29%)
        SKF India2,219.60
        -2457.00 (-52.54%)

        DATA SOURCES: TickerPlant (for live BSE/NSE quotes service) and Dion Global Solutions Ltd. (for corporate data, historical price & volume, F&O data). Sensex & BSE Quotes and Nifty & NSE Quotes are real-time and licensed from BSE and NSE respectively. All timestamps are reflected in IST (Indian Standard Time).

        DISCLAIMER: Any and all content on this website including tools/analysis is provided to you only for convenience and on an “as-is, as- available” basis without representation and warranties of any kind. The content and any output of such tools/analysis is for informational purposes only and should not be relied upon or construed as an investment advice or guarantee for any specific performance/returns advice or considered as recommendation for the purchase or sale of any security or investment. You are advised to exercise caution, discretion and independent judgment with regards to the same and seek advice from professionals and certified experts before taking any decisions.

        By using this site, you agree to the Terms of Service and Privacy Policy.

        The Economic Times